Table 1.
Characteristics of healthy controls and early RA patients.
Fig 1.
FcγR and Igs are increased in early RA.
Expression of FcRs on monocytes (A-B), monocyte bound IgG (C) and IgG serum levels (D) in DMARD- and steroid naive early RA patients (n = 20) compared with healthy controls (HC) (n = 33). (MFI = mean fluorescence intensity).
Table 2.
Fcγ receptor expression and function reflecting severity of joint inflammation in drug naïve early RA patients (n = 20).
Fig 2.
Altered FcγR function in early RA.
IgG1 and IgG3 IC-binding (A-B), ratio of IgG1-IC/IgG3-IC binding (C) and IgG1- and IgG3-IC stimulated TNFα-release (index) (D-E) in DMARD- and steroid naive early RA patients (n = 20) and in healthy controls (HC) (n = 33).
Fig 3.
Effect of methotrexate and prednisolone treatment on monocytes and FcR receptors.
Frequency and expression of CD14 (A), CD64 (B-C), IgG bound to CD64+ cells (D-E) and CD89 (F-G) on monocytes before and after 3–4 months of anti-rheumatic treatment in DMARD- and steroid naive early RA patients (n = 20). (FV = first visit, FU = follow up).
Fig 4.
Reduction of CD64 expression after anti-rheumatic treatment in good responders.
The monocyte expressions of CD64 (A), IgG bound CD64+ cells (B), CD16 (C) and CD89 (D) before and after treatment with methotrexate and prednisolone in early RA patients, defined as good responders (n = 7) or non responders (n = 8). (FV = first visit, FU = follow up, MFI = mean fluorescent intensity).
Fig 5.
Characteristics of good and non responders in early RA.
CRP-concentrations (A), the activating:inhibiting FcR expression ratio (B), and the monocyte CD32b expression (C) in good (n = 7) versus non responders (n = 8) before and after treatment with methotrexate and prednisolone in early RA. (the activating:inhibiting FcR expression ratio was defined as the ratio of the sum of the MFIs of the activating CD64 + CD32a + CD16a divided by the MFI of the inhibiting CD32b).
Fig 6.
Soluble FcR levels in early RA are regulated by anti-rheumatic treatment.
The plasma levels of sCD89 (A), sCD64 (B) and sCD16a (C) in healthy controls (HC)(n = 20), in patients with active polyarticular psoriatic arthritis (PsA) (n = 22), and in early RA patients (n = 19) before and after treatment with anti-rheumatics. (FV = first visit, FU = follow-up).